Table 1.
Characteristics of the patients.
| Characteristics | Overall Population n = 63 |
|---|---|
| Age at the introduction of ICI (year-old) | |
| Median | 68 |
| Range | 62.0–73.5 |
| Gender | |
| Female | 28 (44.5%) |
| Male | 35 (55.5%) |
| Smoking status | |
| Current | 18 (28.6 %) |
| Former | 39 (61.9 %) |
| Never | 6 (9.5 %) |
| Histology | |
| Non squamous | 43 (68.2 %) |
| Squamous | 12 (19.0 %) |
| Other | 8 (12.7 %) |
| Molecular alteration at the diagnostic | |
| KRAS mutation | 22 (34.9 %) |
| BRAF mutation | 4 (6.3 %) |
| EGFR mutation | 2 (3.2 %) |
| MET amplification | 1 (1.6 %) |
| No alteration | 34 (54.0 %) |
| ECOG performance-status at the introduction of ICI | |
| 0–1 | 44 (69.8 %) |
| 2 | 19 (30.2 %) |
| Type of ICI and number of lines before ICI | |
| Pembrolizumab | 20 (31.7 %) |
| First line | 18 (28.6 %) |
| Second line and more | 2 (3.2 %) |
| Nivolumab | 43 (68.3 %) |
| First line | 0 (0 %) |
| Second line and more | 43 (68.3 %) |
Data are expressed as n (%), although otherwise specified.